<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160221</url>
  </required_header>
  <id_info>
    <org_study_id>6416-19</org_study_id>
    <nct_id>NCT04160221</nct_id>
  </id_info>
  <brief_title>Second Trimester Medical Abortion</brief_title>
  <acronym>RAPM</acronym>
  <official_title>Second Trimester Medical Abortion- New Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Mifepristone, an antiprogesterone, and Misoprostol together, has been shown to&#xD;
      make the medial abortion process more efficient and reduce the induction-to-abortion interval&#xD;
      by almost 50%. Despite the recommended 24-48 Mifepristone-Misoprostol interval, recent&#xD;
      retrospective study of a flexible interval, have revealed shorter total abortion time with&#xD;
      shorter intervals. In this study we aim to compare 24 to 12 hours Mifepristone to Misoprostol&#xD;
      intervals&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women are looking for termination of pregnancies in the second trimester, after 12 weeks of&#xD;
      gestation for social and medical reasons, as well as due to intrauterine fetal demise. Both&#xD;
      surgical and medical methods can be used, depending on the patients' preference, providers&#xD;
      skills, availability of drugs and instruments and more. Methods of medical abortion can be&#xD;
      performed with the use of prostaglandin analogues, mifepristone, oxytocin, foley catheter and&#xD;
      osmotic dilators. Misoprostol, a prostaglandin analogue (PGE1), is currently recommended over&#xD;
      other agents due to its efficacy, low cost and ease of use. Misoprostol can be used alone or&#xD;
      in combination with other agents. The use of Mifepristone, an antiprogesterone, and&#xD;
      Misoprostol together, has been shown to make the medial abortion process more efficient and&#xD;
      reduce the induction-to-abortion interval by almost 50%. Current guidelines recommend the use&#xD;
      of Mifepristone 200 mg orally, followed by Misoprostol 400 mcg every 3-4, hours 24-48 later&#xD;
      until expulsion of the fetus. Despite the recommended 24-48 Mifepristone-Misoprostol&#xD;
      interval, recent retrospective study of a flexible interval, ≤12, 12-24 and &gt;24 hours, have&#xD;
      revealed shorter total abortion time (time from Mifepristone to fetal expulsion) with the&#xD;
      shorter intervals. Thus, strict adherence to current guidelines may unnecessarily prolong the&#xD;
      abortion procedure.&#xD;
&#xD;
      Objective Prompted by the need to explore more beneficial methods and regimes for second&#xD;
      trimester medical abortion, we aim to compare 24 to 12 hours Mifepristone to Misoprostol&#xD;
      intervals&#xD;
&#xD;
      Material and Methods Women eligible for second trimester medical abortion will be approached&#xD;
      to enroll in the study at the clinic or emergency room when they arrive to schedule medical&#xD;
      abortion. A research staff member will obtain informed consent. The patient will undergo a&#xD;
      blood test including blood type, complete blood count and chemistry. Basic demographic&#xD;
      information will be collected. A complete history and physical assessment will be performed.&#xD;
      If an ultrasound report is not available to confirm gestational age dating, ultrasound will&#xD;
      be performed to determine gestational age. A baseline cervical exam will be done at this&#xD;
      visit to assess cervical consistency. Patients will be randomized into one of two groups&#xD;
      according to a computer-generated random allocation sequence. Sequentially numbered sealed&#xD;
      opaque envelopes will be used to provide allocation.&#xD;
&#xD;
        -  Patients allocated to group 1 will receive 200 mg Mifepristone orally, followed by&#xD;
           Misoprostol 400 mcg vaginally 12 hours later and subsequently 400 mcg orally every three&#xD;
           hours until fetal expulsion to a maximum of 5 doses.&#xD;
&#xD;
        -  Patients allocated to group 2 will receive 200 mg Mifepristone orally, followed by&#xD;
           Misoprostol 400 mcg vaginally 24 hours later and subsequently 400 mcg orally every three&#xD;
           hours until fetal expulsion to a maximum of 5 doses.&#xD;
&#xD;
      Patients will be discharged home after receiving Mifepristone, and hospitalized upon arrival&#xD;
      for the Misoprostol administration.&#xD;
&#xD;
      If the abortion is not complete after five doses, the woman may be allowed to rest for 12&#xD;
      hours before starting the cycle again.&#xD;
&#xD;
      All participants will be contacted by phone as well as a chart review conducted to assess for&#xD;
      delayed complications. During this follow up time, they will be asked to notify the research&#xD;
      team if they should develop fatigue, malaise, abdominal pain, or jaundice. If these symptoms&#xD;
      occur, a workup for liver injury would be performed. Patients will be asked to obtain repeat&#xD;
      liver function tests within two weeks post-procedure to compare to their baseline hepatic&#xD;
      panel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction-abortion time</measure>
    <time_frame>Through completion of abortion, an estimated period of up to 3 days</time_frame>
    <description>Total induction to complete abortion ( estimated by hours)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>From the beginning until completion of abortion,estimated up to two weeks</time_frame>
    <description>Fever measure above 38 degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive blood loss</measure>
    <time_frame>From the beginning until completion of abortion, estimated up to two weeks</time_frame>
    <description>Excessive blood loss estimated by the medical team ( remnants of blood on pad, active bleeding estimated to be equal to menstruation, heavier bleeding including blood clots, blood loss leading to hemodynamically instability including tachycardia and/or reduced blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any emergency department visit</measure>
    <time_frame>From the beginning until completion of abortion, estimated up to two weeks</time_frame>
    <description>Emergency department visit during the abortion or reported on follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Medical Abortion, Complete or Unspecified, Without Complication</condition>
  <arm_group>
    <arm_group_label>12 hours interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mifepristone followed by Misoprostol treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hours interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mifepristone followed by Misoprostol treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12 hours interval</intervention_name>
    <description>Time interval between treatments</description>
    <arm_group_label>12 hours interval</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>24 hours interval</intervention_name>
    <description>Time interval between treatments</description>
    <arm_group_label>24 hours interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 years and older about to undergo medical second trimester abortion&#xD;
&#xD;
          -  12+0 to 28+0 weeks of gestation&#xD;
&#xD;
          -  Singleton intrauterine pregnancy&#xD;
&#xD;
          -  Able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Allergy to any of the drugs used in the study&#xD;
&#xD;
          -  Genital bleeding of unknown etiology; cancer of the breast, cervix, uterus, or&#xD;
             ovaries; hepatic disease (current or history of)&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Rupture of membranes&#xD;
&#xD;
          -  Taken a CYP3A4 inhibitor within 5 elimination half-lives of the drug from the&#xD;
             procedure&#xD;
&#xD;
          -  Pre-dosing abnormal liver function tests&#xD;
&#xD;
          -  Patients at increased risk of hepatitis based on a history of any of the following:&#xD;
&#xD;
               -  Any history of underlying liver disorder, including hepatitis&#xD;
&#xD;
               -  A family history of hepatitis or currently living with a person 441 who has been&#xD;
                  given a diagnosis of hepatitis&#xD;
&#xD;
               -  A history of or currently working as a sex worker&#xD;
&#xD;
               -  A history of or currently using IV drugs&#xD;
&#xD;
               -  A self-reported history of alcoholic dependency or abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aya A Mohr-Sasson, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aya A Mohr-Sasson, M.D</last_name>
    <phone>97235302777</phone>
    <phone_ext>97235302777</phone_ext>
    <email>mohraya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. A Mohr-Sasson, M.D</last_name>
    <phone>97235302777</phone>
    <phone_ext>97235302777</phone_ext>
    <email>mohraya@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>56506</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. A Mohr-Sasson, M.D</last_name>
      <phone>97235302777</phone>
      <phone_ext>97235302777</phone_ext>
      <email>mohraya@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006714. doi: 10.1002/14651858.CD006714.pub2. Review.</citation>
    <PMID>18254113</PMID>
  </results_reference>
  <results_reference>
    <citation>ACOG Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol. 2013 Jun;121(6):1394-1406. doi: 10.1097/01.AOG.0000431056.79334.cc.</citation>
    <PMID>23812485</PMID>
  </results_reference>
  <results_reference>
    <citation>Borgatta L, Kapp N; Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. Contraception. 2011 Jul;84(1):4-18. doi: 10.1016/j.contraception.2011.02.005. Epub 2011 Mar 30.</citation>
    <PMID>21664506</PMID>
  </results_reference>
  <results_reference>
    <citation>Costescu D, Guilbert É. No. 360-Induced Abortion: Surgical Abortion and Second Trimester Medical Methods. J Obstet Gynaecol Can. 2018 Jun;40(6):750-783. doi: 10.1016/j.jogc.2017.12.010.</citation>
    <PMID>29861084</PMID>
  </results_reference>
  <results_reference>
    <citation>Li HWR, Gemzell-Danielsson K. Mechanisms of action of emergency contraception pills. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):11-12. doi: 10.1080/13625187.2018.1555663. Epub 2019 Jan 21.</citation>
    <PMID>30664367</PMID>
  </results_reference>
  <results_reference>
    <citation>Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421-32. doi: 10.1056/NEJMoa1103180.</citation>
    <PMID>22296076</PMID>
  </results_reference>
  <results_reference>
    <citation>Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003 Nov;68(10-13):1013-7.</citation>
    <PMID>14667994</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Aya Mohr-Sasson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Medical Abortion</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Misoprostol</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

